Breaking News Instant updates and real-time market news.

ICPT

Intercept

$70.79

0.68 (0.97%)

07:04
04/13/18
04/13
07:04
04/13/18
07:04

Intercept announces data from liver biopsy substudy of POISE Phase 3 trial

Intercept Pharmaceuticals announced clinical data from a liver biopsy-based substudy from the POISE Phase 3 trial suggesting that long-term OCA treatment in patients with PBC was associated with reversal or stabilization of fibrosis and cirrhosis. The data are being presented at the International Liver Congress 2018, the 53rd Annual Meeting of the European Association for the Study of the Liver, in Paris, France, from April 11-15, 2018. OCA is not currently indicated for the reversal of fibrosis or cirrhosis in patients with PBC. Prior longitudinal biopsy studies have shown that patients who are not treated with, or have an inadequate response to, ursodeoxycholic acid, the current standard of care, are at significantly higher risk of fibrosis progression, liver failure, transplant and death. Liver biopsy is not the standard of care in PBC and difficult to obtain in clinical trials. In this voluntary substudy of the POISE Phase 3 trial, paired biopsies adequate for analysis were obtained for 13 patients, all of whom had liver fibrosis or cirrhosis at baseline. After three years of treatment with OCA, the majority of patients improved or maintained histological fibrosis stage, while two patients experienced one stage progression. Of the four patients with cirrhosis at baseline, all showed reversal by at least one stage, and three improved to fibrosis without cirrhosis. Pruritus is the most common symptom in patients with PBC and was also the most common adverse event in the POISE Phase 3 substudy. Nine patients experienced pruritus in the substudy, an incidence consistent with the rate observed in the broader study population. A total of five serious adverse events in five patients were reported. All serious adverse events were considered unlikely to be related, or not related, to OCA. A separate poster, "Durable Response in the Markers of Cholestasis through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis," presented at the International Liver Congress provided additional results from the open-label extension of the POISE trial. Sustained improvements in ALP were observed through three years of OCA therapy, with similar improvements seen for GGT, ALT and AST. Mean total bilirubin remained below baseline throughout the three-year open-label period. The most common adverse event observed with OCA therapy was pruritus, resulting in the discontinuation of seven patients during the open-label extension treatment phase. An additional poster, "Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of POISE, 201, and 202," assessed changes in total bilirubin observed in the POISE Phase 3 trial and two Phase 2 trials. The analysis, which included patients with total bilirubin greater than or equal to0.67 times the upper limit of normal at baseline, found that total bilirubin increased after 12 months of placebo treatment and decreased after 12 months of treatment with OCA. In the double-blind phase of POISE, 14% of placebo-treated and 78% of OCA-treated patients with abnormal total bilirubin at baseline attained normal levels after 12 months. Further, of 10 placebo-treated and 20 OCA-treated patients with normal total bilirubin at baseline, 60% of placebo-treated and 15% of OCA-treated patients worsened to abnormal total bilirubin after 12 months. Per EASL clinical guidelines, increasing bilirubin levels - even within the normal range - indicate progressive disease and are strongly associated with adverse clinical outcomes.

  • 13

    Apr

  • 20

    Apr

  • 08

    May

  • 21

    May

ICPT Intercept
$70.79

0.68 (0.97%)

03/28/18
LEER
03/28/18
NO CHANGE
Target $16
LEER
Outperform
More differentiating data at EASL can continue CymaBay momentum, says Leerink
Leerink analyst Joseph Schwartz expects a 6-month Phase 2 study update for CymaBay's (CBAY) seladelpar in primary biliary cholangitis to be reported at the International Liver Congress. The analyst notes CymaBay stock has enjoyed strong momentum since the preliminary 12-week data and he remains optimistic that seladelpar's profile will continue to look differentiated from Intercept's (ICPT) Ocaliva when it comes to safety/tolerability and efficacy in the second-line PBC treatment setting. The analyst reiterates an Outperform rating and $16 price target on CymaBay's shares.
02/13/18
WELS
02/13/18
NO CHANGE
Target $57
WELS
Market Perform
Intercept price target lowered to $57 from $62 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Intercept to $57 from $62 following his most recent review of the FDA AERS Safety Database for marketed bile acid analog OCALIVA, and significant increase in patient deaths in Q4. While Intercept has highlighted an independent safety review of post-marketing safety events cited in a September, 2017 FDA Drug Safety Communication, the analyst believes that significant increase in patient deaths in Q4 is concerning and the rate is above that predicted for the approved OCALIVA patient population by his estimate. Birchenough reiterates a Market Perform rating on the shares.
02/12/18
DBAB
02/12/18
NO CHANGE
Target $103
DBAB
Buy
Intercept study initiation a positive, says Deutsche Bank
Deutsche Bank analyst Navin Jacob views the initiation of the Reverse NASH trial is a positive for Intercept Pharmaceuticals, saying it "puts to rest any lingering bear arguments that OCA is not safe." The trial, if successful, presents potential upside to numbers, Jacob tells investors in a research note. He keeps a Buy rating on the shares with a $103 price target.
02/07/18
GSCO
02/07/18
DOWNGRADE
Target $45
GSCO
Sell
Intercept downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.

TODAY'S FREE FLY STORIES

SGEN

Seattle Genetics

$53.11

-1.73 (-3.15%)

08:03
11/15/18
11/15
08:03
11/15/18
08:03
Hot Stocks
Seattle Genetics receives Breakthrough Therapy Designation for ADCETRIS »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

CUB

Cubic

$63.93

-1.4 (-2.14%)

08:03
11/15/18
11/15
08:03
11/15/18
08:03
Earnings
Cubic sees FY19 revenue $1.37B-$1.45B, consensus $1.3B »

Sees FY19 adjusted EBItDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CUB

Cubic

$63.93

-1.4 (-2.14%)

08:02
11/15/18
11/15
08:02
11/15/18
08:02
Earnings
Cubic reports Q4 EPS 80c vs. 35c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

BIG

Big Lots

$42.56

-1.46 (-3.32%)

08:01
11/15/18
11/15
08:01
11/15/18
08:01
Options
Big Lots put buyer realizes 16% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$64.33

5.73 (9.78%)

08:00
11/15/18
11/15
08:00
11/15/18
08:00
Recommendations
Canada Goose analyst commentary  »

Canada Goose price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

07:59
11/15/18
11/15
07:59
11/15/18
07:59
Upgrade
Mylan rating change  »

Mylan upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$65.09

-2.22 (-3.30%)

07:59
11/15/18
11/15
07:59
11/15/18
07:59
Recommendations
Alnylam analyst commentary  »

Alnylam management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

CUBE

CubeSmart

$29.75

0.46 (1.57%)

07:57
11/15/18
11/15
07:57
11/15/18
07:57
Upgrade
CubeSmart rating change  »

CubeSmart upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$64.33

5.73 (9.78%)

07:56
11/15/18
11/15
07:56
11/15/18
07:56
Recommendations
Canada Goose analyst commentary  »

Canada Goose price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KREF

KKR Real Estate Finance

$20.56

-0.06 (-0.29%)

07:55
11/15/18
11/15
07:55
11/15/18
07:55
Syndicate
KKR Real Estate Finance 4.5M share Spot Secondary priced at $20.15 »

Morgan Stanley, Wells…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

LBTYA

Liberty Global

$24.27

0.6 (2.53%)

07:53
11/15/18
11/15
07:53
11/15/18
07:53
Periodicals
Liberty Global CFO says it is not desperate to divest UPC unit, Reuters reports »

Liberty Global is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ALB

Albemarle

$99.95

0.72 (0.73%)

07:53
11/15/18
11/15
07:53
11/15/18
07:53
Initiation
Albemarle initiated  »

Albemarle initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

PRQR

ProQR Therapeutics

$17.82

-0.84 (-4.50%)

, ONCE

Spark Therapeutics

$40.93

-1.81 (-4.23%)

07:52
11/15/18
11/15
07:52
11/15/18
07:52
Initiation
ProQR Therapeutics, Spark Therapeutics initiated  »

ProQR Therapeutics…

PRQR

ProQR Therapeutics

$17.82

-0.84 (-4.50%)

ONCE

Spark Therapeutics

$40.93

-1.81 (-4.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:50
11/15/18
11/15
07:50
11/15/18
07:50
General news
U.S. retail sales preview: »

U.S. retail sales…

O

Realty Income

$63.17

0.32 (0.51%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Upgrade
Realty Income rating change  »

Realty Income upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRC

Spirit Realty

$8.04

-0.065 (-0.80%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Spirit Realty rating change  »

Spirit Realty downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$17.34

-0.155 (-0.89%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Eagle Point Credit rating change  »

Eagle Point Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFE

Safety, Income and Growth

$18.97

(0.00%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Safety, Income and Growth rating change  »

Safety, Income and Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$25.66

-7.04 (-21.53%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
PG&E rating change  »

Morgan Stanley cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPRT

Essential Properties Realty Trust

$13.96

-0.15 (-1.06%)

07:49
11/15/18
11/15
07:49
11/15/18
07:49
Downgrade
Essential Properties Realty Trust rating change  »

Essential Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$44.35

-0.78 (-1.73%)

07:48
11/15/18
11/15
07:48
11/15/18
07:48
Recommendations
Cisco analyst commentary  »

Value investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Jan

WLK

Westlake Chemical

$71.23

0.07 (0.10%)

07:48
11/15/18
11/15
07:48
11/15/18
07:48
Recommendations
Westlake Chemical analyst commentary  »

Westlake Chemical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$73.26

-1.38 (-1.85%)

07:48
11/15/18
11/15
07:48
11/15/18
07:48
Hot Stocks
Jacobs Engineering selected by Waterbury city for wastewater utility operation »

Jacobs Engineering will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

07:47
11/15/18
11/15
07:47
11/15/18
07:47
Hot Stocks
Breaking Hot Stocks news story on J.C. Penney »

J.C. Penney drops 10.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EPZM

Epizyme

$7.27

-0.31 (-4.09%)

07:46
11/15/18
11/15
07:46
11/15/18
07:46
Conference/Events
Epizyme to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.